IRON

Disc Medicine, Inc.
CAPPED RATING

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Disc Medicine, Inc. (IRON) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D+). The rating has held at C for 3 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
D+
Factor Score 1.6 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -13.8
EV / EBITDA -12.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 8.8%
Price Return 12M 4.2%
Catalyst Signal 0.00
Market Cap $4.0B
TTM Revenue N/A
Price / Sales N/A
ROE -41.3%

Historical Factor Score Progression

Held C for 3 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) D+ (1.7) D+ (1.6) C+ (2.6) C+ (2.6) C (2.2)
2026-11-05 C+ (2.5) D+ (1.7) D+ (1.6) C+ (2.7) C+ (2.7) C (2.2)
2026-10-29 C+ (2.5) D+ (1.7) D+ (1.5) C+ (2.7) C+ (2.7) C (2.2)
2026-10-22 C+ (2.5) D+ (1.6) D+ (1.5) C+ (2.5) C+ (2.6) C (2.2)
2026-10-15 C+ (2.5) D+ (1.6) D+ (1.5) C (2.2) C+ (2.6) C- (2.1)
Page 1 of 3